Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome

NCT02634671 | Completed DMC

• 1 other identifier: 2015-A01247- 42
• Study Type: interventional
• Target: 70
• Locations: 0 countries
• Sites: N/A

Brief Summary

Background: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus, reveal a distinction between the two disorders. Indeed, despite the clinical overlap between the two syndromes, some of the symptoms appear to be specific to only one of them. In particular, the disturbance of visual functions is specifically observed in the 22q11.2DS. Hence, the difficulties in facial emotion recognition in schizophrenia and in the 22q11.DS are likely accounted by different cognitive impairments. Investigating which mechanisms are disturbed would allow a specialized support for patients. Our main hypothesis is that the deficit in facial emotion recognition is more related to visual impairments in the 22q11.2DS than in schizophrenia. This hypothesis will be tested in two groups of patients (22q11.2DS and schizophrenic patients) and a control group (healthy subjects) using an experimental paradigm based on electroencephalography (EEG). A second aim of this study is to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.

Conditions

Schizophrenia

Keywords

schizophrenia; Facial emotions

Outcome Measures

Primary Outcomes (1)

• Steady-state visual evoked potentials (SSVEP) recorded during fast periodic visual stimulation (FPVS).

  SSVEPs arise in response to the periodic presentation of emotional faces. They are analyzed in the frequency domain. Two types of responses are expected: the general visual response (6 Hz and its harmonics) and the expression-specific response (1.2 Hz and its harmonics). Both responses will be compared across the different groups.

  SSVEPs will be recorded during 20 sequences of emotional faces pictures. As each sequence lasts 80s, the EEG recording will be approximately 30-minutes-long.

Study Arms (2)

22Q11

OTHER

24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.

Other: schizophrenia; Other: control group

SCHIZOPHRENIA

OTHER

24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.

Other: the 22q11 deletion syndrome; Other: control group

Interventions

schizophrenia OTHER

The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)

22Q11

the 22q11 deletion syndrome OTHER

The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)

SCHIZOPHRENIA

control group OTHER

The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)

22Q11; SCHIZOPHRENIA

Eligibility Criteria

• Age: 15 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Aged 15-50 years old
• No psychiatric conditions or comorbidity
• Agreement from parents if participant is underage
• Patients with schizophrenia: diagnosis assessed with DSM5 criteria
• Patients with 22q11.2 DS: diagnosis assessed by genetic tests (CGH- array or FISH)
• No mental delay (IQ\>70 according to the fNART)

You may not qualify if:

• Involvement in a current program of social cognition remediation
• Pregnancy
• Substance use disorder (criteria of DSM-5), except for caffeine and tobacco
• Neurologic disorders (vascular, infectious or neurodegenerative)
• Uncorrected visual deficit
• Guardianship
• Medical drugs with cerebral or psychological effect (e.g, corticosteroids)
• Resistance to antipsychotics
• Electroconvulsive therapy in the previous two months

Sponsors & Collaborators

• Hôpital le Vinatier: lead

MeSH Terms

Conditions

Schizophrenia

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Epidemiologic Research Design; Epidemiologic Methods; Investigative Techniques; Research Design; Methods

Study Officials

• DEMILY CAROLINE, PH

  Centre régional de dépistage et de prises en charge des troubles psychiatriques d'origine génétique Pôle Ouest LE VINATIER HOSPITAL

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2015
• First Posted: December 18, 2015
• Study Start: November 1, 2015
• Primary Completion: October 20, 2017
• Study Completion: December 30, 2017
• Last Updated: February 8, 2018

Record last verified: 2018-02